Tauroursodeoxycholic acid affects PPARγ and TLR4 in steatotic liver transplantation

American Journal of Transplantation

Volumn 12, Issue 12, 2012, Pages 3257-3271

  Jimenez Castro M B ^a   Elias Miro, M ^a   Mendes Braz, M ^a,b   Lemoine, A ^c   Rimola, A ^d,e   Rodes J ^a,e   Casillas Ramirez A ^a   Peralta, C ^a,d  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HÔPITAL PAUL BROUSSE   (France)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

ER tress; PPAR ; steatotic liver grafts; TLR4; transplantation; TUDCA

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; BETA INTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHORYL LIPID A; PROTEIN ANTIBODY; ROSIGLITAZONE; TAUROURSODEOXYCHOLIC ACID; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 ANTIBODY; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; LIVER GRAFT; LIVER PROTECTION; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; RAT; UPREGULATION;

ANIMALS; ANTIVIRAL AGENTS; BLOTTING, WESTERN; ENDOPLASMIC RETICULUM; FATTY LIVER; LIVER TRANSPLANTATION; MALE; OBESITY; ORGAN PRESERVATION; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RATS, ZUCKER; REPERFUSION INJURY; TAUROCHENODEOXYCHOLIC ACID; TOLL-LIKE RECEPTOR 4; TRANSPLANTATION, ISOGENEIC; UNFOLDED PROTEIN RESPONSE;

EID: 84870568703     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04261.x     Document Type: Article

References (52)

1. Casillas-Ramírez A, Mosbah IB, Ramalho F, Roselló-Catafau J, Peralta C,. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci 2006; 79: 1881-1894.
2. Angulo P,. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006; 12: 523-534.
3. Nocito A, El-Badry AM, Clavien PA,. When is steatosis too much for transplantation. J Hepatol 2006; 45: 494-499.
4. Elias-Miro M, Massip-Salcedo M, Jiménez-Castro MB, Peralta C,. Does adiponectin benefit steatotic liver transplantation Liver Transpl 2011; 17: 993-1004.
5. Degli Esposti D, Sebagh M, Pham P, et al,. Ischemic preconditioning induces autophagy and limits necrosis in human recipients of fatty liver grafts, decreasing the incidence of rejection episodes. Cell Death Dis 2011; 2: e111: doi:10.1038/cddis.2010.89.
6. Anderson CD, Upadhya G, Conzen KD, et al,. Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts. Liver Transpl 2011; 17: 189-200.
7. Ben Mosbah I, Alfany-Fernández I, Martel C, et al,. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis 2010; 1: 1-12e52.
8. Xu C, Bailly-Maitre B, Reed JC,. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115: 2656-2664.
9. Ozcan U, Yilmaz E, Ozcan L, et al,. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140.
10. Xie Q, Khaoustov VI, Chung CC, et al,. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 2002; 36: 592-601.
11. Setchell KD, Rodrigues CM, Podda M, Crosignani A,. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut 1996; 38: 439-446.
12. Invernizzi P, Setchell KD, Crosignani A, et al,. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 1999; 29: 320-327.
13. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A,. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 40: 693-698.
14. Kaplan MM, Gershwin ME,. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-1273.
15. Baiocchi L, Tisone G, Russo MA, et al,. TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKCalpha-ezrin pathway. Transpl Int 2008; 21: 792-800.
16. Yersiz H, Shaked A, Olthoff K, et al,. Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation 1995; 60: 790-794.
17. Adam R, Cailliez V, Majno P, et al,. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000; 356: 621-627.
18. Villa R, Fondevila C, Erill I, et al,. Real-time direct measurement of human liver allograft temperature from recovery to transplantation. Transplantation 2006; 81: 483-486.
19. Durand F, Renz JF, Alkofer B, et al,. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008; 14: 1694-1707.
20. Nonaka M, Tazuma S, Hyogo H, Kanno K, Chayama K,. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand. J Gastroenterol Hepatol 2008; 23 (7 Pt 2): e198-206.
21. Casillas-Ramírez A, Alfany-Fernández I, Massip-Salcedo M, et al,. Retinol-binding protein 4 and peroxisome proliferator-activated receptor-γ in steatotic liver transplantation. J Pharmacol Exp Ther 2011; 338: 143-153.
22. Zhai D, Zhang J, Zheng Q, Li Z, Zhang J, Tian Y,. Significance of rosiglitazone inhibiting TLR4 expression in partial hepatic ischemia/reperfusion of mice. J Huazhong Univ Sci Technolog Med Sci 2008; 28: 564-567.
23. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A,. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 2010; 4: 659-672.
24. Gao B, Seki E, Brenner DA, et al,. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011; 300: G516-525.
25. Tsung A, Hoffman RA, Izuishi K, et al,. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol 2005; 175: 7661-7668.
26. Zhai Y, Shen XD, O'Connell R, et al,. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173: 7115-7119.
27. Shen XD, Ke B, Zhai Y, et al,. Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant 2005; 5: 1793-1800.
28. Zhai Y, Qiao B, Shen XD, et al,. Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation 2008; 85: 1016-1022.
29. Ellett JD, Atkinson C, Evans ZP, et al,. Toll-like receptor 4 knockout mice are protected from endothelial overactivation in the absence of Kupffer cells after total hepatic ischemia/reperfusion. Liver Transpl 2011; 17: 1089-1098.
30. Jiang N, Zhang X, Zheng X, et al,. Targeted gene silencing of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion injury. Am J Transplant 2011; 11: 1835-1844.
31. Shen XD, Ke B, Zhai Y, et al,. Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl 2007; 13: 1435-1443.
32. Shen XD, Ke B, Uchida Y, et al,. Native macrophages genetically modified to express heme oxygenase 1 protect rat liver transplants from ischemia/reperfusion injury. Liver Transpl 2011; 17: 201-210.
33. Ellett JD, Evans ZP, Atkinson C, Schmidt MG, Schnellmann RG, Chavin KD,. Toll-like receptor 4 is a key mediator of murine steatotic liver warm ischemia/reperfusion injury. Liver Transpl 2009; 15: 1101-1109.
34. Caraceni P, Domenicali M, Vendemiale G, et al,. The reduced tolerance of rat fatty liver to ischemia reperfusion is asociated with mitochondrial oxidative injury. J Surg Res 2005; 124: 160-168.
35. Zhang A, Wang Y, Xie H, Zheng S,. Calcitriol inhibits hepatocyte apoptosis in rat allograft by regulating apoptosis-associated genes. International Immunopharmacology 2007; 7: 1122-1128.
36. Jiménez-Castro MB, Casillas-Ramirez A, Massip-Salcedo M, et al,. Cyclic adenosine 3',5'-monophosphate in rat steatotic liver transplantation. Liver Transpl 2011; 17: 1099-1110.
37. Kamada N, Calne RY,. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979; 28: 47-50.
38. Fernández L, Heredia N, Grande L, et al,. Preconditioning protects liver and lung damage in rat liver transplantation: Role of Xanthine/Xanthine oxidase. Hepatology 2002; 36: 562-572.
39. Miao HL, Qiu ZD, Hao FL, et al,. Significance of MD-2 and MD-2B expression in rat liver during acute cholangitis. World J Hepatol 2010; 2: 233-238.
40. Yang CH, Zhang MS, Li J, Zhang XP, Wang H, Hao YB,. Monophosphoryl lipid A-induced delayed preconditioning in rat small intestine is mediated by calcitonin gene-related peptide. Dig Dis Sci 2011; 56: 1333-1341.
41. An International panel. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658-633.
42. Carrasco-Chaumel E, Roselló-Catafau J, Bartrons R, et al,. Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation. J Hepatol 2005; 43: 997-1006.
43. Serafín A, Roselló-Catafau J, Prats N, Gelpí E, Rodés J, Peralta C,. Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion. Hepatology 2004; 39: 688-698.
44. Fernández L, Carrasco-Chaumel E, Serafín A, et al,. Is ischemic preconditioning a useful strategy in steatotic liver Transplantation. Am J Transplant 2004; 4: 888-899.
45. Rao RV, Ellerby HM, Bredesen DE,. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004; 11: 372-380.
46. Oveson BC, Iwase T, Hackett SF, et al,. Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration. J Neurochem 2011; 116: 144-153.
47. Serafín A, Roselló-Catafau J, Prats N, Xaus C, Gelpí E, Peralta C,. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am J Transplant 2002; 161: 587-601.
48. Yamada S, Ida T, Tabata T, et al,. Alcoholic fatty iver differentially induces a neutrophil-chemokine and hepatic necrosis after ischemia-reperfusion in rat. Hepatology 2000; 32: 278-288.
49. Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, Flavell RA,. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.
50. Nakagawa R, Naka T, Tsutsui H, et al,. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002; 17: 677-687.
51. Yoshimura A, Naka T, Kubo M,. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-465.
52. Sano T, Izuishi K, Hossain MA, et al,. Hepatic preconditioning using lipopolysaccharide: Association with specific negative regulators of the Toll-like receptor 4 signaling pathway. Transplantation 2011; 91: 1082-1089.